- Home
- RIBB vs IVVD Comparison
RIBB vs IVVD Comparison
Compare RIBB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIBB
- IVVD
- Stock Information
- Founded
- RIBB 2024
- IVVD 2020
- Country
- RIBB Japan
- IVVD United States
- Employees
- RIBB N/A
- IVVD N/A
- Industry
- RIBB
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- RIBB
- IVVD Health Care
- Exchange
- RIBB NYSE
- IVVD Nasdaq
- Market Cap
- RIBB 64.9M
- IVVD 69.0M
- IPO Year
- RIBB 2025
- IVVD 2021
- Fundamental
- Price
- RIBB $10.15
- IVVD $0.74
- Analyst Decision
- RIBB
- IVVD Strong Buy
- Analyst Count
- RIBB 0
- IVVD 3
- Target Price
- RIBB N/A
- IVVD $5.85
- AVG Volume (30 Days)
- RIBB 11.9K
- IVVD 1.3M
- Earning Date
- RIBB 01-01-0001
- IVVD 08-13-2025
- Dividend Yield
- RIBB N/A
- IVVD N/A
- EPS Growth
- RIBB N/A
- IVVD N/A
- EPS
- RIBB N/A
- IVVD N/A
- Revenue
- RIBB N/A
- IVVD $36,688,000.00
- Revenue This Year
- RIBB N/A
- IVVD $446.60
- Revenue Next Year
- RIBB N/A
- IVVD $112.63
- P/E Ratio
- RIBB N/A
- IVVD N/A
- Revenue Growth
- RIBB N/A
- IVVD N/A
- 52 Week Low
- RIBB $9.95
- IVVD $0.35
- 52 Week High
- RIBB $10.45
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- RIBB N/A
- IVVD 48.03
- Support Level
- RIBB N/A
- IVVD $0.70
- Resistance Level
- RIBB N/A
- IVVD $0.77
- Average True Range (ATR)
- RIBB 0.00
- IVVD 0.05
- MACD
- RIBB 0.00
- IVVD -0.00
- Stochastic Oscillator
- RIBB 0.00
- IVVD 45.94
About RIBB RIBBON ACQUISITION CORP
Ribbon Acquisition Corp is a blank check company.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.